Navigation Links
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
Date:6/6/2009

- Late-Breaking Data from Pivotal BLOOM Trial Presented at the American Diabetes Association's 69th Scientific Sessions Expand on Previously Announced Positive Top-Line Results -

NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today a late-breaking poster presentation of positive results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management, at the American Diabetes Association's 69th Scientific Sessions. Lorcaserin patients achieved highly significant categorical and absolute weight loss in Year 1, and continued treatment with lorcaserin in Year 2 helped significantly more patients maintain their weight loss as compared to those on placebo. Treatment with lorcaserin also resulted in highly significant improvements as compared to placebo in multiple secondary endpoints associated with cardiovascular risk. Lorcaserin did not result in increased risk of depression and was not associated with the development of cardiac valvular insufficiency.

Previously announced BLOOM data demonstrated that lorcaserin was highly efficacious, achieving statistical significance on all three co-primary efficacy endpoints, and was very well tolerated. The BLOOM results also satisfy the efficacy requirement in the most recent US Food and Drug Administration, or FDA, draft guidance for the development of drugs for weight management.

"These data provide reason for new optimism for the millions of people who struggle with managing their weight and are in need of novel, well tolerated treatments to help improve their overall health," said Steven R. Smith, M.D., Co-Principal Investigator and Professor and Assistant Director for Clinical Research at
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
2. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
5. Critical Pharmaceuticals Enter Sustained Release hGH Arena
6. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
9. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
11. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Fla., Dec. 1, 2011  Hybrid Fuels, Inc. (Pink Sheets: ... acquired 100% of the shares of EMG Marketing Solutions, ... sales, marketing and product development expertise to the multi-billion ... a wholly owned subsidiary of Hybrid Fuels. ...
... 2011 HASCO Medical, Inc. (OTCBB: HASC), www.mysouthernmed.com ... serves patients in Alabama, Florida, and Mississippi, announced today ... Ocala, Florida. The acquisition closed on November 16, 2011. ... supplier that has been located in the Ocala, Florida ...
Cached Medicine Technology:Hybrid Fuels, Inc. Acquires Marketing Company Focused on Multi-Billion Dollar Nutraceutical/Pharmaceutical Industry 2HASCO Medical Announces Approval to Acquire Certified Medical and Certified Auto of Ocala 2HASCO Medical Announces Approval to Acquire Certified Medical and Certified Auto of Ocala 3
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... drug which is typically used for treating colorectal cancer. ... treating gastric cancer and pancreatic cancer. TS-1 is composed ... first approved in 1999 in Japan for the treatment ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
(Date:12/25/2014)... December 25, 2014 When head lice hits ... in a frenzy to get rid of it while keeping ... in Coral Gables now have the solution right in their ... clinic location, Lice Troopers provides full spectrum head lice screening ... Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, ...
(Date:12/25/2014)... News) -- The risk of burns from fires and ... to be extra cautious, an expert says. "Between ... increase in patients coming in with burns," said Dr. ... Firefighters Burn Center of Stony Brook University Hospital in ... joy, but if not careful, could quickly turn tragic," ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2
... disorder have slightly higher death rate, study shows , TUESDAY, ... celiac disease face a slightly higher risk of dying than ... disease were the main causes of death in the patients ... had small-intestinal biopsies in childhood, the researchers found. , Celiac ...
... , NEW YORK, Sept. 15 The U.S. ... as its newest board member. Brutto, who serves as president of ... development experience to the Fund, which serves as the primary fundraising ... , , A native of Chicago, Brutto oversees ...
... , NASHVILLE, Tenn., Sept. 15 Hospital Corporation ... the InformationWeek 500, which lists the nation,s most innovative users of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20050825/CLTH069LOGO ) , , ... 2009 at an awards ceremony held during the InformationWeek 500 Conference ...
... Indiana University School of Medicine scientists have received ... the federal economic stimulus legislation, funding that has ... the medical center campus. More than 40 ... awards ranging from a $1.4 million National Science ...
... , , , SARASOTA Fla., Sept. ... 15th anniversary of helping seniors do more than they think they can ... a dreaded diagnosis or has a health crisis, family members often are ... Kobritz RN, head of Youthful Aging Home Health Care, the caregivers simply ...
... , BURBANK, Calif., Sept. 15 A ... and the Childrens Hospital Los Angeles Medical Group has been developed ... a group that nationwide falls in a gap between adult and ... The Adolescent & Young Adult Cancer Program is believed ...
Cached Medicine News:Health News:UPS Chief Named to U.S. Fund for UNICEF's Board of Directors 2Health News:Hospital Corporation of America Recognized by InformationWeek as One of Nation's Most Innovative Users of Business Technology 2Health News:Indiana U medical researchers boost research and jobs with stimulus legislation grants 2Health News:Indiana U medical researchers boost research and jobs with stimulus legislation grants 3Health News:Indiana U medical researchers boost research and jobs with stimulus legislation grants 4Health News:Seniors May Think They Can't, But They Can 2Health News:Young Adults with Cancer Focus of Program Developed by Providence Saint Joseph Medical Center and Childrens Hospital Los Angeles 2Health News:Young Adults with Cancer Focus of Program Developed by Providence Saint Joseph Medical Center and Childrens Hospital Los Angeles 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: